Article info

Download PDFPDF

Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease

Authors

  • Esther Lutgens Department of Medical Biochemistry, Amsterdam Cardiovascular Sciences (ACS), Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilian’s University, Munich, Germany German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany PubMed articlesGoogle scholar articles
  • Tom T.P. Seijkens Department of Medical Biochemistry, Amsterdam Cardiovascular Sciences (ACS), Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Tom T.P. Seijkens; t.t.seijkens{at}amsterdamumc.nl
View Full Text

Citation

Lutgens E, Seijkens TT
Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease

Publication history

  • Accepted January 22, 2020
  • First published February 6, 2020.
Online issue publication 
February 06, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.